Arcus Biosciences' falling revenue is concerning despite its...
Arcus Biosciences' falling revenue is concerning despite its reassuring cash runway. Though the forecast of reaching breakeven soon is positive, the potential for share dilution due to further cash raising is a risk for shareholders.
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment